About Xcell Biosciences
Xcell Biosciences is a company based in San Francisco (United States) founded in 2012. Xcell Biosciences has raised $40.9 million across 4 funding rounds from investors including Illumina, LabCorp and Casdin Capital. The company has 11 employees as of December 31, 2022. Xcell Biosciences offers products and services including AVATAR Foundry, AVATAR Odyssey, and AVATAR AI. Xcell Biosciences operates in a competitive market with competitors including 10X Genomics, Denali Therapeutics, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 11 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xcell Biosciences Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$40.9 M (USD)
in 4 rounds
-
Latest Funding Round
$1.4 M (USD), Series B
Dec 06, 2024
-
Investors
Illumina
& 6 more
-
Employee Count
11
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xcell Biosciences
Xcell Biosciences offers a comprehensive portfolio of products and services, including AVATAR Foundry, AVATAR Odyssey, and AVATAR AI.
Scalable platform for cell therapy manufacturing in tumor environments.
Platform for cell therapy research and preclinical applications.
Tool to measure and enhance cell therapy potency effectively.
People of Xcell Biosciences
Unlock access to complete
Funding Insights of Xcell Biosciences
Xcell Biosciences has successfully raised a total of $40.9M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $1.4 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $1.4M
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series B - Xcell Biosciences | Valuation |
investors |
|
| Jan, 2022 | Amount | Series B - Xcell Biosciences | Valuation | Casdin Capital | |
| Feb, 2017 | Amount | Series A - Xcell Biosciences | Valuation | HBM Genomics |
|
Investors in Xcell Biosciences
Xcell Biosciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, LabCorp and Casdin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Investment in life sciences innovation is facilitated by Dynamk Capital.
|
Founded Year | Domain | Location | |
|
Investments in early-stage biotech startups are made by Formic Ventures.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xcell Biosciences
Financial Statements - Xcell Biosciences
Xcell Biosciences Comparisons
Competitors of Xcell Biosciences
Xcell Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Denali Therapeutics, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Latest news on Xcell Biosciences
Frequently Asked Questions about Xcell Biosciences
Xcell Biosciences was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Xcell Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Xcell Biosciences is a funded company, having raised a total of $40.9M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on Jul 30, 2015.
As of Dec 31, 2022, the latest employee count at Xcell Biosciences is 11.
Xcell Biosciences was founded in 2012 in San Francisco, United States, focusing on biotechnology for cancer research. A platform technology named Avatar is utilized to replicate in vivo conditions, enabling reproducible in vitro testing. Circulating tumor cells from patient blood are isolated and expanded through this system. Complementary cell-binding substrates and culture media are supplied. An AI-enabled tool is provided for real-time assessment of cell health, kinetics, and immunotherapy targets.
Xcell Biosciences's top competitors include Juno Therapeutics, 10X Genomics and Personalis.
Xcell Biosciences offers AVATAR Foundry, AVATAR Odyssey, and AVATAR AI.
Xcell Biosciences has 7 investors. Key investors include Illumina, LabCorp, Casdin Capital, Dynamk Capital, and Formic Ventures.